University Health Network

The Medical College of Wisconsin, Inc.

University of Virginia Patent Foundation

Washington University

Armour Therapeutics Inc.

Jeffrey A Medin

Sean Devine

Christopher J Paige

Robyn A A Oldham

Lawrence G Lum

Archana Thakur

John F Dipersio

Murtaza S Nagree

Mary L Faber

Joshua Daniel Silvertown

Everett R Tate

Alastair J S Summerlee

The present invention provides novel bispecific antibodies that bind to human CD30 and uses thereof. Methods of treating cancer using the bispecific antibodies described herein are also provided.

CD30 bispecific antibodies and method of immunotherapy of CD30+ malignancies

The present invention is related to a dual promoter lentiviral vector and methods of use for the treatment of diseases and disorders, specifically lysosomal storage disorders.

andenrichment strategy targeting lymphocytes derived from vector transduced HSCs for therapy of disorders

The present invention provides novel antibodies and antigen binding fragments thereof that bind to human CD30. Also presented are single chain variable antibodies, chimeric antigen receptors and uses thereof. Methods of treating cancer are also disclosed.

Anti-CD30 antibodies and methods for treating CD30+ cancer

Compositions and methods for delivering immune modulatory molecules to result in a therapeutic effect are disclosed. The compositions and methods use stably integrating lentiviral delivery systems. The methods are useful for therapeutically and prophylactically treating cancer such as leukemia.

IL-12 immunotherapy for cancer

The application relates to a composition comprising a stably integrating delivery vector, a modified mammalian thymidylate kinase (tmpk) that increases phosphorylation of a prodrug relative to phosphorylation of the prodrug by wild-type human tmpk, and a detection cassette fused to the tmpk. The application also relates to use of these compositions in methods of treatment of diseases, such as graft versus host disease and cancer.

Thymidylate kinase fusions and uses thereof

Compositions and methods far delivering immune modulatory molecules to result in a therapeutic effect are disclosed. The compositions and methods use stably integrating lentiviral delivery systems. The methods are useful for therapeutically and prophylactically treating cancer such as leukemia.

The application relates to a composition comprising: a stably integrating delivery vector; a modified mammalian thymidylate kinase (tmpk) wherein the modified mammalian tmpk increases phosphorylation of a prodrug relative to phosophorylation of the prodrug by wild-type human tmpk; and a detection cassette fused to tmpk. The application also relates to use of these compositions in methods of treatment of diseases such as graft versus host disease and cancer.

Modified H2 relaxms which act as antagonists of the relaxm receptor in cells and tissues, in particular, modified H2 relaxms comprising one or more alterations of the ammo acid sequence at positions B 13, B17 and B20 located in the receptor binding domain The antagonists retain affinity to the receptor, but do not substantially activate the receptor once bound thereto The H2 relaxm antagonists are used in compositions and methods for the treatment of cancers wherein a relaxm receptor is expressed.

Growing community of inventors

North York, Canada

Jeffrey A Medin